Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL665139 | 0.97 | PARP1 (0.60) | PARP1PKMHTR2BPOLBKDM4E | |
| SCHEMBL664093 | 0.96 | PARP1 (0.58) | PARP1PKMHTR2BPOLBKDM4E | |
| SCHEMBL664849 | 0.92 | PKM (0.58) | PARP1PKMHTR2BALDH1A1TSHR | |
| SCHEMBL632795 | 0.90 | HTR2B (0.54) | PARP1PKMHTR2BPOLBKDM4E | |
| SCHEMBL740834 | 0.90 | POLB (0.53) | PARP1PKMHTR2BPOLBKDM4E | |
| SCHEMBL666506 | 0.87 | PARP1 (0.57) | PARP1PKMHTR2BPOLB | |
| SCHEMBL665174 | 0.86 | PARP1 (0.56) | PARP1PKMHTR2B | |
| SCHEMBL663064 | 0.85 | PARP1 (0.60) | PARP1PKMHTR2BPOLBKDM4E | |
| SCHEMBL665267 | 0.84 | PARP1 (0.59) | PARP1PKMHTR2BPOLBKDM4E | |
| SCHEMBL2674802 | 0.79 | HTR2B (0.55) | HTR2BPOLBKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120045524-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2012-02-23 | — | — | US | disclosed |
| US-20110151023-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152336-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110151023-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885PKM 450/4885HTR2B 1566/4885 |
| US-20110152336-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885PKM 450/4885HTR2B 1566/4885 |
| US-20120045524-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885PKM 450/4885HTR2B 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.